Recombinant human tissue plasminogen activator protects the basal lamina in experimental focal cerebral ischemia
Dorothe Burggraf, Helge K. Martens, Gabriele Jäger, Gerhard F. Hamann
Department of Neurology, Ludwig-Maximilians-University Munich, Klinikum Großhadern, Munich, Germany
Summary
While recombinant tissue plasminogen activator (rt-PA) is
successfully used in human ischemic stroke, it may also cause
hemorrhagic complications. Animal experiments have shown
that hemorrhages are related to microvascular basal lamina
damage.We investigated the effects of different doses of rt-PA
on the brain microvasculature. Experimental cerebral ischemia
in rats was induced for 3 h and followed by 24 h reperfusion
(suture model). Each group of rats (n = 6) received either treatment
(0.9, 9, or 18 mg rt-PA/kg body weight) or saline (control
group) at the end of ischemia. The loss of microvascular basal
lamina antigen collagen type IV was measured by Western blot
of the ischemic and non-ischemic basal ganglia and cortex.
Compared with the contralateral non-ischemic area, collagen
type IV was significantly reduced in the ischemic area: (basal ganglia/cortex) 43% +/- 9% / 64% +/- 4 %. Low/moderate doses
of rt-PA had a protective effect: 0.9 mg 79% +/- 3% / 89% +/-
6%, 9 mg 72% +/- 9%/ 81% +/- 12% (p < 0.05). Higher doses of
rt-PA (18 mg) had a similar effect as seen in untreated controls:
57% +/- 11% / 59% +/- 9% (p < 0.05,Anova). MMP-9 and MMP-
2, measured by gelatine zymography, steadily increased over
higher doses of rt-PA: MMP-9 (basal ganglia/cortex): control
115% +/- 4% / 123% +/- 3% compared with 18 mg rt-PA 146%
+/- 5%/ 162% +/- 6% (p < 0.05) and MMP-2: control 109% +/-
4%/ 116% +/- 5% and 18 mg rt-PA 222% +/- 15%/ 252% +/- 2%
(p < 0.05). Low to moderate doses of rt-PA protect the
microvascular basal lamina, whereas high doses of rt-PA have
the opposite effect, probably due to increased coactivation of
MMP-2 and MMP-9.